No Data
Organigram Global's Products Recognized at the CNB Awards
Organigram Global Shares Insights From OG Investor Session
New Abacus Data Poll Reveals That Most Canadians See Cannabis as a Key Pillar of Canada's Economic Future
A. G. P. Maintains OrganiGram(OGI.US) With Buy Rating, Raises Target Price to $2.16
Alliance Global Partners Sticks to Its Buy Rating for OrganiGram Holdings (OGI)
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
